About

Daniel Miller, MD, is an Associate Professor in the Department of Dermatology at the University of Minnesota. His research focuses on cutaneous graft-versus-host disease, inflammatory dermatopathology, and melanoma. Clinically, he specializes in hospital dermatology, adverse drug reactions, and dermatopathology. For appointments, contact can be made via the provided phone number. His academic and clinical work is based at the Phillips-Wangensteen Building in Minneapolis, Minnesota.

Research topics

• Medicine
• Internal medicine
• Immunology
• Dermatology
• Virology
• Pediatrics
• Surgery
• Gastroenterology
• Pathology

Selected publications

• Congenital Melanocytic Nevus with Neurocristic Cutaneous Hamartoma: A Case Report

  Dermatopathology · 2025-04-10 · 4 citations

  articleOpen access

  Congenital melanocytic nevi (CMN) are benign tumors present at birth or arising in the first few months of life. A small subset of these nevi present with mild atypical features and heterogeneous differentiation, including Schwannian differentiation. We present a case of a 3-week-old with a 7 cm red/purple scalp nodule consistent with CMN with mild atypical heterogeneous areas. On histology, there were dermal nests of spindle cells in a fibrillar matrix, with increased vessels and clusters of small round melanocytes interspersed between collagen bundles and around adnexal structures. The lesion also exhibited rare pagetoid ascent of melanocytes as single cells and nests. Overall, these features were consistent with a CMN with nodular proliferative neurocristic cutaneous hamartoma (NCH) with a component of a compound mild atypical melanocytic proliferation. Next generation sequencing (NGS) identified a novel SH2B1::BRAF fusion. This case highlights the diagnostic challenges of heterogeneous differentiation within CMN in young children.

  PublisherOA PDFDOI

• Use of dupilumab in eczematous eruptions following hematopoietic cell transplantation

  JAAD Case Reports · 2025-08-18

  articleOpen access
  PublisherDOI

• Multifocal Kaposiform Hemangioendothelioma Successfully Treated With Sirolimus Monotherapy

  Pediatric Dermatology · 2025-08-17 · 1 citations

  articleOpen access

  Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that typically presents in infancy and may be associated with the Kasabach-Merritt phenomenon (KMP). We present a challenging case of multifocal KHE on the leg of an infant, initially suspected at birth to be a reticulate port wine birthmark. Skin biopsy and imaging supported the rare diagnosis of multifocal KHE. Complicated by KMP, he was started on sirolimus monotherapy with significant improvement in his widespread disease.

  PublisherOA PDFDOI

• Multifocal Kaposiform Hemangioendothelioma Successfully Treated With Sirolimus Monotherapy

  UNC Libraries · 2025-08-28

  articleOpen access

  Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that typically presents in infancy and may be associated with the Kasabach-Merritt phenomenon (KMP). We present a challenging case of multifocal KHE on the leg of an infant, initially suspected at birth to be a reticulate port wine birthmark. Skin biopsy and imaging supported the rare diagnosis of multifocal KHE. Complicated by KMP, he was started on sirolimus monotherapy with significant improvement in his widespread disease.

  PublisherDOI

• Grading differentiation in cutaneous squamous cell carcinoma: A modified Delphi consensus panel

  Journal of the American Academy of Dermatology · 2025-05-08 · 1 citations

  article
  PublisherDOI

• Alternative Dosing of Eltrombopag for the Treatment of Chronic, Steroid-Refractory Immune Thrombocytopenia

  Cureus · 2024-06-26

  articleOpen accessCorresponding

  Idiopathic thrombocytopenic purpura (ITP) presents challenges in management, particularly in cases refractory to corticosteroids. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, offer alternative therapeutic options. We report a case of a 72-year-old South Asian male with steroid-refractory chronic ITP who achieved a favorable response with biweekly eltrombopag dosing. Platelet response was comparable to daily dosing, suggesting the efficacy of less frequent administration schedules. This approach may enhance patient adherence and reduce treatment-related financial burdens. Biweekly eltrombopag dosing presents a promising alternative for chronic ITP management, warranting further investigation.

  PublisherOA PDFDOI

• Methods for health workforce projection model: systematic review and recommended good practice reporting guideline

  Human Resources for Health · 2024-04-17 · 23 citations

  reviewOpen access

  BACKGROUND: Health workforce projection models are integral components of a robust healthcare system. This research aims to review recent advancements in methodology and approaches for health workforce projection models and proposes a set of good practice reporting guidelines. METHODS: We conducted a systematic review by searching medical and social science databases, including PubMed, EMBASE, Scopus, and EconLit, covering the period from 2010 to 2023. The inclusion criteria encompassed studies projecting the demand for and supply of the health workforce. PROSPERO registration: CRD 42023407858. RESULTS: Our review identified 40 relevant studies, including 39 single countries analysis (in Australia, Canada, Germany, Ghana, Guinea, Ireland, Jamaica, Japan, Kazakhstan, Korea, Lesotho, Malawi, New Zealand, Portugal, Saudi Arabia, Serbia, Singapore, Spain, Thailand, UK, United States), and one multiple country analysis (in 32 OECD countries). Recent studies have increasingly embraced a complex systems approach in health workforce modelling, incorporating demand, supply, and demand-supply gap analyses. The review identified at least eight distinct types of health workforce projection models commonly used in recent literature: population-to-provider ratio models (n = 7), utilization models (n = 10), needs-based models (n = 25), skill-mixed models (n = 5), stock-and-flow models (n = 40), agent-based simulation models (n = 3), system dynamic models (n = 7), and budgetary models (n = 5). Each model has unique assumptions, strengths, and limitations, with practitioners often combining these models. Furthermore, we found seven statistical approaches used in health workforce projection models: arithmetic calculation, optimization, time-series analysis, econometrics regression modelling, microsimulation, cohort-based simulation, and feedback causal loop analysis. Workforce projection often relies on imperfect data with limited granularity at the local level. Existing studies lack standardization in reporting their methods. In response, we propose a good practice reporting guideline for health workforce projection models designed to accommodate various model types, emerging methodologies, and increased utilization of advanced statistical techniques to address uncertainties and data requirements. CONCLUSIONS: This study underscores the significance of dynamic, multi-professional, team-based, refined demand, supply, and budget impact analyses supported by robust health workforce data intelligence. The suggested best-practice reporting guidelines aim to assist researchers who publish health workforce studies in peer-reviewed journals. Nevertheless, it is expected that these reporting standards will prove valuable for analysts when designing their own analysis, encouraging a more comprehensive and transparent approach to health workforce projection modelling.

  PublisherOA PDFDOI

• PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report

  Drugs in R&D · 2024-06-01 · 4 citations

  articleOpen accessSenior author

  BACKGROUND AND OBJECTIVE: PD-1 inhibitors have revolutionized cancer therapies and are being used to treat an expanding array of cancers. To best serve patients, clinicians should be familiar with the spectrum of skin manifestations associated with PD-1 inhibitor therapy. Here, we report a unique case of hypertrophic lichen planus (HLP) in a 64-year-old man treated with pembrolizumab; the presentation initially suggested a squamous cell carcinoma (SCC) morphology, then evolved into a morphology more typical of hypertrophic lichen planus. This case underscores the need for caution in diagnosing eruptive SCCs associated with PD-1 inhibitor therapy. In such instances, maintaining a high suspicion for lichenoid reactions as sequelae of PD-1 inhibitor treatment and starting an empiric trial of therapy for lichenoid dermatitis may be warranted to ensure timely management of lesions. METHODS: We describe a case of hypertrophic lichen planus mimicking squamous cell carcinoma in the setting of PD-1 inhibitory therapy with pembrolizumab. A PubMed literature review was conducted to identify other cases and determine the incidence of lichenoid reactions imitating squamous cell carcinoma in the setting of PD-1 inhibitor use. RESULTS: Our case is one of the few available pieces of literature describing eruptive hypertrophic lichen planus imitating SCC in the setting of PD-1 inhibitor use. Initial skin nodule biopsy appeared histologically compatible with squamous cell carcinoma. Repeat biopsy of the skin lesions revealed histological features consistent with hypertrophic lichen planus. Over time, lower extremity lesions evolved into a more typical appearance of hypertrophic lichen planus. Treatment with topical 0.05% clobetasol ointment and oral acitretin 25 mg led to complete resolution of lesions within 2-3 months. CONCLUSIONS: This case underscores the significance of maintaining vigilance for lichenoid reactions as potential sequelae of PD-1 inhibitor therapy. It highlights the variability in initial presentation and the potential for lesions to transform over time. Timely recognition and appropriate management, including high-potency topical corticosteroids and oral acitretin, are crucial for achieving favorable outcomes in patients experiencing such reactions. More studies are necessary to fully analyze the rate of HLP occurrence as a consequence of PD-1 inhibitor use.

  PublisherOA PDFDOI

• PA11 An indolent course of paediatric primary cutaneous γ/δ T-cell lymphoma

  British Journal of Dermatology · 2024-06-28

  articleOpen accessSenior author

  Abstract A 16-year-old girl with a history of antinuclear antibody (ANA) positivity, Raynaud phenomenon, arthralgias and night sweats presented to our paediatric dermatology clinic for relapsing and remitting tender subcutaneous nodules on the trunk and extremities over the past year. The nodules arise spontaneously within a couple of days and resolve over a few days or up to a month later without overlying skin changes or ulceration. At one time, she had six nodules altogether, but typically she has one to four nodules that come and go every month. Prior rheumatology evaluation had considered systemic lupus erythematosus; however, multiple repeated autoimmune serologies had returned negative, including repeat ANAs, extractable nuclear antigen antibody panels, and DNA double-stranded antibodies. Physical exam at the initial dermatology visit demonstrated a single small deep subcutaneous nodule on the left buttock. Inflammatory panniculitis was suspected and a biopsy was considered, but it was ultimately deferred given that the present nodule was very deep and already resolving. The patient returned to clinic a year later given continued formation of subcutaneous nodules. An incisional punch biopsy from her right flank was performed, which revealed a subcutaneous, predominantly lobular infiltrate of mostly CD3-positive T cells with prominent atypia, high Ki-67 labelling, significant positivity on T-cell receptor δ immunostaining and cytotoxic markers, and a positive T-cell gene rearrangement study. These findings were consistent with primary cutaneous γ/δ T-cell lymphoma (PCGD-TCL). The patient was subsequently referred to haematology and oncology. Peripheral blood smear, positron emission tomography scan, and bone marrow biopsy were reassuring, with no evidence of haemophagocytic syndrome or malignancy. Treatment with methotrexate was initiated and the patient experienced some mild improvement initially; however, the nodules soon returned to the same frequency and intensity as before. Interestingly, she did report resolution of her night sweats since starting methotrexate. Currently, she is seeking additional expert opinions with consideration for a repeat biopsy, as well as second-line therapies such as ciclosporin, mycophenolate or bexarotene. PCGD-TCL is a rare lymphoma of γ/δ T cells that usually presents with generalized subcutaneous nodules or ulceronecrotic plaques, and is classically associated with a poor prognosis. The apparent indolent course in this patient supports the notion that PCGD-TCL may be more heterogeneous than traditionally described, and a subset of PCGD-TCL follows a more indolent course analogous to the α/β phenotype of subcutaneous panniculitis-like T-cell lymphoma. This case also highlights a rare paediatric presentation of PCGD-TCL and the often overlapping clinical and microscopic features of the panniculitic cutaneous lymphomas with lupus panniculitis.

  PublisherOA PDFDOI

• Toxic Epidermal Necrolysis Superimposed on Severe Drug Rash With Eosinophilia and Systemic Symptoms Complicated by Fatal Hemophagocytic Lymphohistiocytosis: A Case Report

  Cureus · 2024-09-16 · 2 citations

  articleOpen access

  Drug rash with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse reaction (SCAR) characterized by an extensive skin rash associated with visceral organ involvement, fever, eosinophilia, atypical lymphocytosis, and lymphadenopathy. Toxic epidermal necrolysis (TEN) is a more severe, distinct adverse cutaneous reaction that causes extensive necrosis and detachment of the epidermis, involving over 30% of the body surface area (BSA). Hemophagocytic lymphohistiocytosis (HLH), a form of excessive immune activation, is known to be associated with SCARs such as DRESS. We present a peculiar case of overlap between different SCARs to reiterate their gravity, a severe form of DRESS triggered by the use of allopurinol overlapping with the aggressive TEN possibly from interaction with vancomycin administered for severe sepsis, which was complicated by a fatal case of HLH.

  PublisherOA PDFDOI

Frequent coauthors

• Garry Lachhar

  Icahn School of Medicine at Mount Sinai

  36 shared

• Salman Syed

  36 shared

• Marc Ganz

  State University of New York

  36 shared

• Harinder Sawhney

  Queens Hospital Center

  36 shared

• Hadassah Stein

  36 shared

• Cuong V. Nguyen

  Biostatistical Consulting (United States)

  11 shared

• Noah Goldfarb

  University of Minnesota

  8 shared

• Ronda S. Farah

  University of Minnesota

  7 shared